This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Case Report
A Case Report of Classical Gastrointestinal Stromal Tumor with an Undifferentiated Pleomorphic Sarcoma Component
SHUNHAI JIAN
Affiliated Hospital of North Sichuan Medical College
Corresponding Author
ORCiD: https://orcid.org/0000-0002-5940-1365
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background:Gastrointestinal stromal tumor (GIST) is the most common primary mesenchymal neoplasm of the gastrointestinal tract.a small number of GIST patients showed morphologic and immunohistochemical phenotypes change after taking the selective tyrosine kinase inhibitor imatinib.
Case presentation :A 64-year-old Asian man was referred to a hospital for dizziness and anemia. Then the patient received imatinib for 11 months after the discovery of a gastric stromal tumor, and had the tumor surgically removed. We found that the classical GIST region was juxtaposed to a undifferentiated component of pleomorphic sarcoma. The genetic test results of the patient showed that the 11 exon of C-Kit gene was homozygous deletion, and the 567 codon of the 12 exon of PDGFRα was homozygous mutation. We infer that the patient showed rare dedifferentiation change after taking the tyrosine kinase inhibitors (TKIs) imatinib（IM）.
Conclusions:Together with reported cases, awareness of this rare clinical entity and its potential occurrence following Tyrosine kinase inhibitor (TKI)treatment could prevent a diagnostic pitfall. The case report reminds us of the diagnosis in GIST that the possibility of dedifferentiation in GISTs should always be considered when an undifferentiated sarcoma component is identified in the gastrointestinal tract.
Keywords
Gastrointestinal stromal tumor(GIST), Imatinib (IM), undifferentiated pleomorphic sarcoma
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 17 Sep, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint. It has not completed peer review.
Case Report
A Case Report of Classical Gastrointestinal Stromal Tumor with an Undifferentiated Pleomorphic Sarcoma Component
SHUNHAI JIAN
Affiliated Hospital of North Sichuan Medical College
Corresponding Author
ORCiD: https://orcid.org/0000-0002-5940-1365
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 17 Sep, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background:Gastrointestinal stromal tumor (GIST) is the most common primary mesenchymal neoplasm of the gastrointestinal tract.a small number of GIST patients showed morphologic and immunohistochemical phenotypes change after taking the selective tyrosine kinase inhibitor imatinib.
Case presentation :A 64-year-old Asian man was referred to a hospital for dizziness and anemia. Then the patient received imatinib for 11 months after the discovery of a gastric stromal tumor, and had the tumor surgically removed. We found that the classical GIST region was juxtaposed to a undifferentiated component of pleomorphic sarcoma. The genetic test results of the patient showed that the 11 exon of C-Kit gene was homozygous deletion, and the 567 codon of the 12 exon of PDGFRα was homozygous mutation. We infer that the patient showed rare dedifferentiation change after taking the tyrosine kinase inhibitors (TKIs) imatinib（IM）.
Conclusions:Together with reported cases, awareness of this rare clinical entity and its potential occurrence following Tyrosine kinase inhibitor (TKI)treatment could prevent a diagnostic pitfall. The case report reminds us of the diagnosis in GIST that the possibility of dedifferentiation in GISTs should always be considered when an undifferentiated sarcoma component is identified in the gastrointestinal tract.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9